Valuation: Grifols, S.A.

Capitalization 5.58B 6.54B 5.16B 4.86B 9.05B 609B 9.26B 60.69B 23.69B 292B 24.56B 24.03B 1,042B P/E ratio 2026 *
11.2x
P/E ratio 2027 * 8.27x
Enterprise value 13.97B 16.38B 12.91B 12.17B 22.67B 1,525B 23.19B 152B 59.32B 732B 61.48B 60.17B 2,609B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.62x
Free-Float
79.4%
Yield 2026 *
2.17%
Yield 2027 * 2.95%
1 day+0.61%
1 week-2.93%
Current month-0.25%
1 month-9.96%
3 months-21.56%
6 months-26.13%
Current year-16.50%
1 week 8.79
Extreme 8.794
9.57
1 month 8.43
Extreme 8.432
9.7
Current year 8.43
Extreme 8.432
11.7
1 year 7.66
Extreme 7.66
13.7
3 years 6.36
Extreme 6.362
15.92
5 years 6.36
Extreme 6.362
25.94
10 years 6.36
Extreme 6.362
34.31
Manager TitleAgeSince
Chief Executive Officer 57 31/03/2024
Chief Tech/Sci/R&D Officer 52 31/08/2024
Comptroller/Controller/Auditor 47 31/12/2015
Director TitleAgeSince
Director/Board Member 69 07/12/2024
Director/Board Member 70 07/12/2024
Chairman 76 24/01/2010
Change 5d. change 1-year change 3-years change Capi.($)
+0.61%-2.93%+20.89%-3.31% 6.47B
-2.47%-1.70%+29.85%-9.64% 78.8B
+1.18%+3.97%+112.60%+219.62% 60.53B
-0.57%+57.10%+57.10%+57.10% 49.49B
-0.74%+0.19%-40.42%-53.63% 47.58B
-2.34%-2.46%+43.56%-39.69% 25.99B
-0.62%+3.58%+91.08%-67.80% 20.34B
-0.92%+0.15%+63.22%+27.23% 19.3B
+1.04%+1.35%+64.72%+61.96% 14.9B
-1.23%+1.97%+126.86%+377.83% 14.64B
Average -0.34%+1.03%+56.94%+56.97% 33.8B
Weighted average by Cap. -0.66%+1.15%+50.98%+51.35%

Financials

2026 *2027 *
Net sales 7.81B 9.16B 7.22B 6.8B 12.67B 852B 12.96B 84.95B 33.16B 409B 34.37B 33.64B 1,459B 8.33B 9.76B 7.69B 7.25B 13.51B 909B 13.82B 90.55B 35.35B 436B 36.63B 35.86B 1,555B
Net income 536M 629M 496M 467M 870M 58.54B 890M 5.83B 2.28B 28.09B 2.36B 2.31B 100B 734M 860M 678M 639M 1.19B 80.08B 1.22B 7.98B 3.12B 38.43B 3.23B 3.16B 137B
Net Debt 8.39B 9.84B 7.75B 7.31B 13.62B 916B 13.93B 91.27B 35.63B 439B 36.92B 36.14B 1,567B 7.94B 9.31B 7.34B 6.92B 12.89B 867B 13.18B 86.39B 33.72B 416B 34.95B 34.21B 1,483B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (2.9%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Employees
25,258
Date Price Change Volume
10/04/26 8.934 +0.61% 2,889,963
09/04/26 8.880 -5.93% 7,383,256
08/04/26 9.440 +4.33% 3,299,293
07/04/26 9.048 -1.69% 2,463,741
02/04/26 9.204 -0.71% 1,803,941
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
8.934EUR
Average target price
14.96EUR
Spread / Average Target
+67.48%

Quarterly revenue - Rate of surprise